Risks of recurrence for GH and PET reported in the NICE and SOGC guidelines.

<p>*Recurrence more likely in women with higher BMI, and when the prior PET was: of early onset, “severe”, or complicated by eclampsia or HELLP syndrome (SOGC).</p>†<p>The following traditional PET risk markers for first occurrence do NOT influence recurrence: multiple gestation, change of partner, and long interpregnancy interval (SOGC).</p>¤<p>25% if complication of PET let to birth <34 weeks (NICE).</p>§<p>55% if complications let to birth <28 weeks (NICE).</p><p>Risks of recurrence for GH and PET reported in the NICE and SOGC guidelines.</p

Grading systems for assessing the strength of recommendations.

<p>Grading systems for assessing the strength of recommendations.</p

Grading systems for assessing the levels of evidence^*.

<p>*Bold indicates comparable gradings for ‘high quality’ evidence. Italic indicates comparable shading for ‘low quality’ evidence.</p>†<p>Does NOT include meta-analysis of RCTs.</p>‡<p>includes small studies and retrospective studies as well.</p><p>Grading systems for assessing the levels of evidence^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113715#nt102" target="_blank">*</a>}.</p

Clinical Practice Guideline domain scores using the AGREE-II instrument, with details of content included where relevant.

<p>*Scores represent the consensus of both reviewers, following independent assessment and discussion (numbers indicate scores and proportions are of the total score for each domain).</p><p>Clinical Practice Guideline domain scores using the AGREE-II instrument, with details of content included where relevant.</p

General description of included Clinical Practice Guidelines.

<p>*Guidelines developed for community/midwifery use, ^Δ The supplement was considered as an appendix, ^† The executive summary was regarded as an appendix, ^§ Represents all references for all chapters and includes duplicates, ¤ Recommendations presented in 3 boxes and 2 tables.</p><p>General description of included Clinical Practice Guidelines.</p

Demographic and clinical characteristics of women with severe/non-severe pre-eclampsia according to MgSO4 use (N = 631).

<p>Demographic and clinical characteristics of women with severe/non-severe pre-eclampsia according to MgSO4 use (N = 631).</p

Determinants included in the final model for magnesium sulphate use in all pre-eclampsia^a.

<p>Determinants included in the final model for magnesium sulphate use in all pre-eclampsia<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189966#t002fn002" target="_blank">^a</a>.</p

Maternal death and severe maternal morbidity rates among women with prolapsed membranes at 22–25 vs 26–28 weeks gestation (singleton pregnancies without congenital anomalies).

<p>Maternal death and severe maternal morbidity rates among women with prolapsed membranes at 22–25 vs 26–28 weeks gestation (singleton pregnancies without congenital anomalies).</p

Pregnancy complications, labour characteristics and interventions among women with prolapsed membranes at 22–25 vs 26–28 weeks gestation (singleton pregnancies without congenital anomalies).

<p>Pregnancy complications, labour characteristics and interventions among women with prolapsed membranes at 22–25 vs 26–28 weeks gestation (singleton pregnancies without congenital anomalies).</p

Proportion of undelivered pregnancies after a diagnosis of prolapsed membranes at 22–25 vs 26–28 weeks’ gestation among women with non-anomalous singleton pregnancies.

<p>Proportion of undelivered pregnancies after a diagnosis of prolapsed membranes at 22–25 vs 26–28 weeks’ gestation among women with non-anomalous singleton pregnancies.</p